RT Journal Article
T1 Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up.
A1 Santos-Garcia, Diego
A1 de-Deus, Teresa
A1 Cores, Carlos
A1 Canfield, Hector
A1 Paz-Gonzalez, Jose M
A1 Martinez-Miro, Cristina
A1 Valdes-Aymerich, Lorena
A1 Suarez, Ester
A1 Jesus, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellas, Lluis
A1 Cosgaya, Marina
A1 Garcia-Caldentey, Juan
A1 Caballol, Nuria
A1 Legarda, Ines
A1 Hernandez-Vara, Jorge
A1 Cabo, Iria
A1 Lopez-Manzanares, Lydia
A1 Gonzalez-Aramburu, Isabel
A1 Avila-Rivera, Maria A
A1 Catalan, Maria J
A1 Nogueira, Victor
A1 Puente, Victor
A1 Dotor, Julio
A1 Borrue, Carmen
A1 Solano, Berta
A1 Alvarez-Sauco, Maria
A1 Vela, Lydia
A1 Escalante, Sonia
A1 Cubo, Esther
A1 Carrillo, Francisco
A1 Martinez-Castrillo, Juan C
A1 Sanchez-Alonso, Pilar
A1 Alonso, Gemma
A1 Lopez-Ariztegui, Nuria
A1 Gaston, Itziar
A1 Kulisevsky, Jaime
A1 Blazquez, Marta
A1 Seijo, Manuel
A1 Ruiz-Martinez, Javier
A1 Valero, Caridad
A1 Kurtis, Monica
A1 de-Fabregues, Oriol
A1 Ardura, Jessica
A1 Alonso, Ruben
A1 Ordas, Carlos
A1 Lopez-Diaz, Luis M
A1 McAfee, Darrian
A1 Martinez-Martin, Pablo
A1 Mir, Pablo
K1 Parkinson’s disease
K1 mood
K1 non-motor symptoms
K1 progression
K1 quality of life
AB Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients . The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group , and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods : PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males , mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males , mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory ) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.
PB MDPI AG
SN 2075-4426
YR 2021
FD 2021-06-30
LK http://hdl.handle.net/10668/18132
UL http://hdl.handle.net/10668/18132
LA en
NO Santos-García D, de Deus T, Cores C, Canfield H, Paz González JM, Martínez Miró C, et al. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. J Pers Med. 2021 Jun 30;11(7):626.
DS RISalud
RD Apr 20, 2025